MIST
Milestone Pharmaceuticals Inc.
Healthcare · Biotechnology · NMS
$1.23
Data: 2026-05-14
✗ ETHICAL FAIL

MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$206M
Total market value of the company
Trailing P/E
0.00
Forward P/E
-1.82
Based on estimated future earnings — lower means cheaper
Rev Growth
0.0%
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
ROE
-229.7%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$7.40
+502% from current price — median analyst estimate
Recommendation
STRONG_BUY
Consensus view from 5 analysts covering this stock
About Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

https://www.milestonepharma.com

Country: Canada Employees: 38 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
28.4% PASS
Debt must be below 33% of total assets
Cash Ratio
51.5% FAIL
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
DISTRIBUTION
Smart money appears to be selling into strength — caution
Sharpe Ratio
0.444
Positive but modest risk-adjusted returns
Kelly Fraction
-0.0334
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.109
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-8.0%
Historical annualised return based on price data
Max Drawdown
-72.9%
Largest peak-to-trough decline — the worst it has been
HMM State
BEAR
Statistical model detects bearish conditions
Days in State
12
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
1.04
Moves slightly more than the broader market
52W High
$3.06
60% below the year high
52W Low
$1.00
23% above the year low
Avg Volume
2,048,485
Average daily shares traded — higher means easier to buy and sell
Short Ratio
3.1
Days it would take all short sellers to cover — higher means more crowded
Short % Float
6.6%
Moderate short interest
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$-0.75
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
1.40
Meaningful debt load — monitor closely
Current Ratio
8.01
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
7.83
Like current ratio but excludes inventory — stricter test
Gross Margin
100.0%
Revenue left after cost of goods — higher means pricing power
Operating Margin
-1,116.2%
Profit from core operations before interest and tax
Free Cash Flow
$-28,903,250
Negative — the business is spending more than it generates
Revenue (TTM)
$2M
Total revenue over the last 12 months
Net Income
$-63,058,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
5
Target High
$8.00
Target Median
$7.40
Target Low
$6.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2026-04-16 OLIVETO JOSEPH GERARD Chief Executive Officer 36,500 $82,490
2026-01-26 OLIVETO JOSEPH GERARD Chief Executive Officer 66,600 —
2026-01-26 MULLER LORENZ ANDREW Officer 20,100 —
2026-01-26 HASIJA AMIT Chief Financial Officer 20,100 —
2026-01-26 BHARUCHA DAVID Officer 20,100 —
2026-01-26 NELSON JEFFREY EDWARD Chief Operating Officer 20,100 —
2026-01-26 OLIVETO JOSEPH GERARD Chief Executive Officer 167,577 $375,315
2026-01-26 MULLER LORENZ ANDREW Officer 64,746 $145,851
2026-01-26 HASIJA AMIT Chief Financial Officer 70,252 $158,209
2026-01-26 BHARUCHA DAVID Officer 70,252 $158,209
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-14

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.